The Centers for Medicare and Medicaid Services has finalised the FY 2027 hospice payment rule (CMS-1851-F), issued 30 July 2026 and published in the Federal Register on 3 August at 91 FR 49118. For hospice elections beginning on or after 1 October 2026, hospices must give every Medicare beneficiary or their representative the hospice election statement addendum: the written list, with rationale, of the conditions, items, services and drugs the hospice has determined are unrelated to the terminal illness and related conditions, and which it will therefore not cover. Since October 2020 the addendum had to be produced only if someone asked for it. CMS said the request-only framework had not achieved its purpose, and in its April proposal defined the time of election as within the first five days of the election's effective date.

The addendum's content requirements at 42 CFR 418.24(c) carry over. The document must be updated when the hospice's coverage determinations change, must be kept in the medical record, and must be available to non-hospice providers and Medicare contractors. A signature is acknowledgement of receipt only, not agreement with the hospice's determinations; if the person refuses to sign, the hospice must record why on the form itself. The addendum must also state that immediate advocacy is available through the Medicare Beneficiary and Family Centered Care Quality Improvement Organization for anyone who disagrees with the hospice's decision. Alongside the rule, CMS published provider-level scores from its service and spending variation index (SSVI) for FY 2024 and FY 2025: a score from 0 to 16 built from nine claims-based measures, including the share of beneficiaries with stays of 180 days or more, live discharge rates, average minutes of direct care per routine home care day, weekend days with at least one skilled visit, live discharges who return to the same hospice within seven days, and both total non-hospice spending and non-hospice spending per day. A higher score signals a potentially higher level of concern and possible targeted education or oversight; CMS is explicit that it is not by itself a finding of fraud, waste or abuse.

The dementia relevance is in the spending analysis CMS published with the rule. In the April 2026 proposed rule, CMS reported that Medicare paid more than $2.8 billion in non-hospice spending during a hospice election in FY 2024 across Parts A, B and D, with Parts A and B alone rising from nearly $790 million in FY 2020 to over $2 billion, an increase of about 160 percent. Of that FY 2024 non-hospice spending, 30.1 percent was tied to a primary hospice diagnosis of Alzheimer's disease, dementia or Parkinson's, the largest single grouping, ahead of heart conditions at 25.9 percent. CMS also reported that 67 percent of non-hospice spending occurred after day 60 of the hospice election, the territory where dementia stays commonly sit. Part D non-hospice drug spending rose from $552.9 million in FY 2020 to $813.1 million in FY 2024.

Hospice trade groups objected. The final payment update is 2.3 percent, an estimated $755 million, below the 2.4 percent proposed, with the FY 2027 aggregate cap set at $36,174.75. Jennifer Sheets, chief executive of the National Alliance for Care at Home, described the index as resting on "a fundamentally flawed methodology that penalizes legitimate providers for non-hospice claims they have no visibility into", and said there is no process to review or correct the data before publication. LeadingAge, the Alliance and NPHI argued the mandatory addendum adds paperwork and may confuse families without addressing what drives spending outside the benefit. CMS used more recent claims data for the final SSVI but made no substantive change to the methodology, and said the measures and scoring may change as it considers feedback and shifts in hospice practice.